

is

(FILE 'HOME' ENTERED AT 17:35:09 ON 30 OCT 2001)

FILE 'BIOSIS' ENTERED AT 17:35:46 ON 30 OCT 2001

L1 0 S ALA DEFICIENCY PORPHYRIA TREATMENT  
L2 0 S TRATMENT ALA DEFICIENCY PORPHYRIA  
L3 0 S PORPHYRIAS TREATMENT (W) ENZYMES  
L4 1 S PORPHYRIAS TREATMENT  
L5 1 S PORPHYRIA CUTANEA TARDA (W)TREATMENT  
L6 0 S HEREDITARY COPROPORPHYRIA (W) TREATMENT  
L7 0 S TREATMENT (W) COPROPORPHYRINOGEN OXIDASE  
L8 0 S COPROPORPHYRINOGEN ADMINISTRATION  
L9 0 S UROPORPHYRINOGEN DECARBOXYLASE ADMINISTRATION  
L10 0 S UROPORPHYRINOGEN DECARBOXYLASE (A)ADMINISTRATION  
L11 0 S COPROPORPHYRINOGEN OXIDASE (A) ADMINISTRATION  
L12 0 S PROTOPORPHYRINOGEN OXIDASE (A) ADMINISTRATION  
L13 0 S UROPORPHYRINOGEN III SYNTHASE (A) ADMINISTRATION  
L14 0 S UROPORPHYRINOGEN DECARBOXYLASE (A) ADMINISTRATION  
L15 450 S UROPORPHYRINOGEN DECARBOXYLASE  
L16 1 S L15 AND CLINICAL APPLICATION  
L17 0 S PORPHOBILINOGEN DEAMINASE (A) CLINICAL APPLICATION

FILE 'STNGUIDE' ENTERED AT 17:53:44 ON 30 OCT 2001

L18 0 S ALA DEHYDRATASE (A)CLINICAL APPLICATION  
L19 0 S UROPORPHYRINOGEN OXIDASE (A) CLINICAL APPLICATION  
L20 0 S COPROPORPHYRINOGEN OXIDASE  
L21 0 S UROPORPHYRINOGEN III SYNTHASE (A) CLINICAL APPLICATION  
L22 0 S CLINICAL APPLICATION (A) FERROCHELATASE

FILE 'CAPLUS' ENTERED AT 17:59:26 ON 30 OCT 2001

L23 0 S L1  
L24 0 S L2  
L25 0 S L3  
L26 1 S L4  
L27 4 S L5  
L28 4 S L5  
L29 0 S L6  
L30 0 S L7  
L31 0 S L8  
L32 0 S L9  
L33 0 S L10  
L34 0 S L11  
L35 0 S L12  
L36 0 S L13  
L37 0 S L14  
L38 359 S L15  
L39 0 S CLINICAL APPLICATION (A)L38  
L40 0 S L38 (A) TREATMENT  
L41 359 S L15  
L42 0 S L16  
L43 0 S L17  
L44 0 S PORPHOBILINOGEN DEAMINASE (A) ADMINISTRATION  
L45 0 S PORPHOBILINOGEN DEAMINASE (A)CLINICAL APPLICATION  
ADMINISTRAT  
L46 0 S PORPHOBILINOGEN DEAMINASE (A)CLINICAL APPLICATION  
L47 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTIC USE  
L48 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTICAL COMPOSITION  
USE  
L49 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTICAL COMPOSITION

L50 0 S L18  
L51 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTICAL USE  
L52 0 S PORPHOBILINOGEN DEAMINASE (A) TREATMENT  
L53 0 S PORPHOBILINOGEN DEAMINASE (A) ADMINISTRATION  
L54 0 S PORPHOBILINOGEN DEAMINASE (A) PHARMACEUTICAL COMPOSITION  
L55 0 S TREATMENT (W) PORPHOBILINOGEN DEAMINASE

FILE 'USPATFULL' ENTERED AT 18:13:34 ON 30 OCT 2001

L56 0 S L1  
L57 0 S L54  
L58 0 S PORPHOBILINOGEN DEAMINASE (A) CLINICAL APPLICATION  
L59 0 S L55

FILE 'EUROPATFULL' ENTERED AT 18:15:41 ON 30 OCT 2001

L60 0 S L44  
L61 0 S L45  
L62 0 S L46  
L63 0 S L47  
L64 0 S L48  
L65 0 S L49  
L66 0 S L50  
L67 0 S L51  
L68 0 S L52  
L69 0 S L53  
L70 0 S L54  
L71 0 S L55

=>

d 11 300 bib

L1 ANSWER 300 OF 441 MEDLINE  
AN 91346824 MEDLINE  
DN 91346824 PubMed ID: 1878585  
TI **Enzyme replacement therapy** for Gaucher  
disease.  
AU Beutler E; Kay A; Saven A; Garver P; Thurston D; Dawson A; Rosenbloom B  
CS Department of Molecular and Experimental Medicine, Research Institute of  
Scripps Clinic, La Jolla, CA 92037.  
NC DK36639 (NIDDK)  
RR00833 (NCRR)  
SO BLOOD, (1991 Sep 1) 78 (5) 1183-9.  
Journal code: A8G; 7603509. ISSN: 0006-4971.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 199109  
ED Entered STN: 19911020  
Last Updated on STN: 20000303  
Entered Medline: 19910927

1640